Histopathological insights into treatment failure with the levonorgestrel releasing intrauterine system in women with heavy menstrual bleeding: a retrospective study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20260178Keywords:
Heavy menstrual bleeding, Endometrial pathology, Leiomyoma, Adenomyosis, Levonorgestrel-releasing intrauterine system, Treatment failureAbstract
Background: The levonorgestrel-releasing intrauterine system (LNG-IUS) is an established first-line therapy for heavy menstrual bleeding (HMB), effectively reducing menstrual blood loss and improving quality of life in most women. However, a subset of patients fails to achieve adequate response, warranting evaluation of potential underlying causes.
Methods: This retrospective study was conducted at BARC Hospital, Mumbai, from January 2017 to March 2020, and included 88 women with HMB treated with LNG-IUS. Non-responders were identified based on persistent heavy bleeding despite therapy. Endometrial biopsy and, where applicable, hysterectomy specimens were analyzed to determine histopathological findings associated with treatment failure.
Results: Of the 88 women treated, 26 (29.5%) were classified as non-responders. Endometrial biopsy revealed proliferative endometrium in 65.4%, disordered proliferative endometrium in 19.2%, and secretory endometrium in 15.4% of cases. Among nine non-responders who underwent hysterectomy, adenomyosis was the most common finding (44.4%), followed by adenomyosis with leiomyoma (33.3%), endometrial polyp (11.1%), and leiomyoma (11.1%).
Conclusions: Treatment failure of LNG-IUS in women with HMB was predominantly associated with structural uterine abnormalities, particularly adenomyosis. Comprehensive pre-insertion evaluation, including clinical and imaging assessment, is essential to detect underlying pathology and optimize patient selection. Individualized management based on uterine morphology and symptom profile may improve therapeutic success and reduce delays in achieving symptom control.
Metrics
References
Munro MG, Critchley HOD, Fraser IS. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Int J Gynaecol Obstet. 2011;113(1):3-13. DOI: https://doi.org/10.1016/j.ijgo.2010.11.011
Nidhi, Kumari A, Tirkey S, Prakash J. Effectiveness of levonorgestrel-releasing intrauterine system in perimenopausal women with heavy menstrual bleeding: a prospective study at a teaching hospital in India. J Menopausal Med. 2022;28(3):128-35. DOI: https://doi.org/10.6118/jmm.22025
Chen S, Liu J, Peng S, Zheng Y. Levonorgestrel intrauterine system versus medical therapy for heavy menstrual bleeding: A systematic review and meta-analysis. Front Med. 2022;9:948709. DOI: https://doi.org/10.3389/fmed.2022.948709
Struble J, Reid S, Bedaiwy MA. Adenomyosis: a clinical review of a challenging gynecologic condition. J Minim Invasive Gynecol. 2016;23(2):164-85. DOI: https://doi.org/10.1016/j.jmig.2015.09.018
Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2015;30(4):CD002126. DOI: https://doi.org/10.1002/14651858.CD002126.pub3
Wildemeersch D, Janssens D, Andrade A. Management of heavy menstrual bleeding in the community: long-term efficacy of the levonorgestrel-releasing intrauterine system. Eur J Contracept Reprod Health Care. 2018;23(3):206-12.
Xiao B, Wu SC, Chong J, Zeng T, Han LH, Luukkainen T. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003;79(4):963-9. DOI: https://doi.org/10.1016/S0015-0282(02)04913-0
Wiebe E, Trussell J. Discontinuation rates and acceptability during 1 year of using the levonorgestrel intrauterine ball. Contraception. 2016;93(4):364-6. DOI: https://doi.org/10.1016/j.contraception.2015.12.002
Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy and safety of the levonorgestrel intrauterine system (LNG-IUS) in menorrhagia: a pilot study from India. Int J Gynaecol Obstet. 2007;97(3):190-4. DOI: https://doi.org/10.1016/j.ijgo.2007.01.009
Taran FA, Wallwiener M, Kabashi D, Rothmund R, Rall K, Kraemer B, et al. Clinical characteristics indicating adenomyosis at the time of hysterectomy: a retrospective analysis. Arch Gynecol Obstet. 2012;285(6):1571-6. DOI: https://doi.org/10.1007/s00404-011-2180-7
Vercellini P, Consonni D, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod. 2014;29(5):964-77. DOI: https://doi.org/10.1093/humrep/deu041
Shaaban OM, Ali MK, Sabra AM, Abd El Aal DE. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial. Contraception. 2015;92(4):301-7. DOI: https://doi.org/10.1016/j.contraception.2015.05.015
Downloads
Published
How to Cite
Issue
Section
